诊断学理论与实践

诊断学理论与实践 ›› 2026, Vol. 25 ›› Issue (01): 63-70.doi: 10.16150/j.1671-2870.2026.01.009

• 论著 • 上一篇    下一篇

ARGLU1在宫颈癌组织中的表达及与临床病理特征及预后的关系

卢沭雄, 唐海旭, 吴萍, 采丽, 张颖, 颜霞()   

  1. 扬州大学医学院附属淮安市妇幼保健院病理科，江苏 淮安 223007
  • 收稿日期:2025-06-25 修回日期:2026-01-01 接受日期:2026-01-04 出版日期:2026-02-25 发布日期:2026-02-25
  • 通讯作者: 颜霞 E-mail： yxyzytk@126.com
  • 基金资助:
    淮安市科技计划资助项目(HAB202335)

Expression of ARGLU1 in cervical cancer tissues and its relationship with clinicopathological characteristics and prognosis

LU Shuxiong, TANG Haixu, WU Ping, CAI Li, ZHANG Ying, YAN Xia()   

  1. Department of Pathology, Huai'an Maternal and Child Healthcare Hospital Affiliated to Yangzhou University Medical Aca-demy, Jiangsu Huai'an 223007, China
  • Received:2025-06-25 Revised:2026-01-01 Accepted:2026-01-04 Published:2026-02-25 Online:2026-02-25

RichHTML

3

PDF (PC)

18

摘要：

目的：探讨富含精氨酸和谷氨酸蛋白1（arginine and glutamate rich 1，ARGLU1）在宫颈癌组织中的表达，及其与宫颈癌患者临床病理特征及预后之间的关系，为探索宫颈癌发生分子机制的研究提供新线索。方法：收集本院2024年1月至2024年11月间连续入组的32例宫颈癌患者的癌组织和癌旁组织新鲜组织样本；另收集152例宫颈癌患者的癌组织石蜡样本，其中本院病例63例（2020年6月至2023年3月收集，术后随访至2025年6月，随访时间为2.33~5.08年），组织芯片病例89例（2010年1月至2011年10月收集，术后随访至2017年3月，随访时间为5.50~7.25年），采用实时荧光定量聚合酶链式反应（quantita-tive real-time polymerase chain reaction， qRT-PCR）检测、免疫组织化学方法检测宫颈癌与相应癌旁组织中的ARGLU1 mRNA和蛋白表达差异，分析ARGLU1表达与宫颈癌患者临床病理特征之间的关系，并应用Kaplan-Meier法进行预后评估。结果：宫颈癌组织中的ARGLU1 mRNA相对表达量显著高于癌旁组织[（2.72±0.52）比（1.33±0.44），P<0.05]，且宫颈癌组织中ARGLU1蛋白的高表达率也显著高于癌旁组织（68.75%比28.13%，χ²=10.573，P<0.05）。有淋巴结转移的宫颈癌患者的ARGLU1高表达率、ARGLU1 mRNA相对表达量均高于无淋巴结转移宫颈癌患者[86.49%（32/37）比66.09%（76/115），χ²=5.664，P<0.05；（3.177±0.255）比（2.539±0.482），t=-3.748，P<0.05]，且不同临床分期的宫颈癌患者间的ARGLU1高表达率、ARGLU1 mRNA相对表达量差异有统计学意义[Ⅰ期58.18%（32/55），Ⅱ期69.23%（27/39），Ⅲ期77.78%（28/36），Ⅳ期95.45%（21/22），χ²=11.654，P<0.05；Ⅰ期（2.489±0.518），Ⅱ期（2.919±0.426），Ⅲ期（2.930±0.257），Ⅳ期（3.340±0.071），t=3.393，P<0.05]。单因素生存分析显示，宫颈癌患者的年龄、宫颈癌分期、淋巴结是否转移以及ARGLU1表达的高低是影响宫颈癌患者预后的因素（P<0.05）。多因素Cox风险模型分析结果表明，年龄、宫颈癌分期、淋巴结转移以及ARGLU1表达量是宫颈癌患者预后的独立影响因子（P<0.05）。Kaplan-Meier法预后分析显示，ARGLU1高表达患者的5年总生存率、5年无病生存率均明显低于低表达患者（44%比84%，Log-rank χ²=14.580，P<0.05；43%比83%，Log-rank χ²=14.736，P<0.05）。结论：ARGLU1在宫颈癌组织中高表达，且与不良病理特征及不良预后密切相关，提示ARGLU1可能在宫颈癌发生、发展中起重要作用，有望作为潜在的预后标志物和治疗靶点。

关键词: 宫颈癌, 富含精氨酸和谷氨酸蛋白1, 临床病理特征, 预后, 治疗靶点

Abstract:

Objective To investigate the expression of arginine and glutamate rich protein 1 (ARGLU1) in cervical cancer tissues and its relationship with clinicopathological characteristics and prognosis in cervical cancer patients, and to provide new clues for exploring the molecular mechanisms of cervical cancer development. Methods Fresh tissue samples of cancer tissues and adjacent tissues were collected from 32 consecutive cervical cancer patients diagnosed and treated at our hospital from January 2024 to November 2024. Additionally, paraffin-embedded samples of cancer tissue were collected from 152 cervical cancer patients, including 63 cases from our hospital (collected from June 2020 to March 2023, with postoperative follow-up until June 2025, follow-up duration ranging from 2.33 to 5.08 years) and 89 cases from a tissue microarray (collected from January 2010 to October 2011, with postoperative follow-up until March 2017, follow-up duration ranging from 5.50 to 7.25 years). Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to detect the differences in ARGLU1 mRNA and protein expression between cervical cancer tissues and corresponding adjacent tissues. The relationship between the expression of ARGLU1 and the clinicopathological characteristics of cervical cancer patients was further analyzed, and prognosis was assessed using the Kaplan-Meier method. Results The relative expression of ARGLU1 mRNA in cervical cancer tissues was significantly higher than that in adjacent tissues [(2.72±0.52) vs. (1.33±0.44), (P<0.05)], and the high expression rate of ARGLU1 protein in cervical cancer tissues was also significantly higher than that in adjacent tissues (68.75% vs. 28.13%, χ²=10.573, P<0.05). The high expression rate of ARGLU1 and the relative expression level of ARGLU1 mRNA in cervical cancer patients with lymph node metastasis were higher than those in patients without lymph node metastasis [86.49% (32/37) vs. 66.09% (76/115), χ²=5.664, P<0.05; (3.177±0.255) vs. (2.539±0.482), t=-3.748, P<0.05]. Moreover, the differences in the high expression rate of ARGLU1 and the relative expression level of ARGLU1 mRNA among cervical cancer patients at different clinical stages were statistically significant [Stage Ⅰ 58.18% (32/55), Stage Ⅱ 69.23% (27/39), Stage Ⅲ 77.78% (28/36), Stage Ⅳ 95.45% (21/22), χ²=11.654, P<0.05; Stage Ⅰ (2.489±0.518), Stage Ⅱ (2.919±0.426), Stage Ⅲ (2.930±0.257), Stage Ⅳ (3.340±0.071), t=3.393, P<0.05]. Univariate survival analysis showed that the age of cervical cancer patients, the stage of cervical cancer, lymph node metastasis status, and the level of ARGLU1 expression were the factors affecting the prognosis of cervical cancer patients (P<0.05). The results of multivariate Cox risk model analysis showed that age, tumor stage, lymph node metastasis status, and ARGLU1 expression level were independent factors influencing the prognosis of cervical cancer patients (P<0.05). Prognostic analysis using the Kaplan-Meier method showed that patients with high ARGLU1 expression had significantly lower 5-year overall survival rate and 5-year disease-free survival rate compared to patients with low expression (44% vs. 84%, Log-rank χ²=14.580, P<0.05; 43% vs. 83%, Log-rank χ²=14.736, P<0.05). Conclusions ARGLU1 is highly expressed in cervical cancer tissues and is closely associated with adverse pathological features and poor prognosis, suggesting that ARGLU1 may play a significant role in the development and progression of cervical cancer, and it may serve as a potential prognostic biomarker and therapeutic target.

Key words: Cervical cancer, Arginine and glutamate rich 1, Clinicopathological features, Prognosis, Therapeutic target

中图分类号: